"Liposomes as a platform for CD40 ligand presentation for the purpose o" by Sydney Bone

Author

Sydney Bone

Date of Award

2025

Document Type

Thesis

Degree Name

Master of Science in Engineering (MSE)

Department

Chemical Engineering

Committee Chair

Kyung-Ho Roh

Committee Member

Paresh Kumar Samantaray

Committee Member

Agnieszka Truszkowska

Research Advisor

Kyung-Ho Roh

Subject(s)

B cells, Cultures (Biology), Liposomes, Lymphocyte transformation

Abstract

Improvement of in-vitro culture of immune cells is critical for expanding our understanding of the immune system and advancing the treatment of diseases, whether pathogenic, cancerous, or autoimmune, via cellular immunotherapies. This study aims to develop a feeder-free B cell culture system using biomaterials-based presentation of a critical signaling molecule, namely CD40 ligand (CD40L). Traditional B cell culture methods rely on allogenic feeder cells to present CD40L, but a culture of only autologous cells is preferable for cellular immunotherapies. Previous work of our lab established an effective feeder-free B cell culture system using magnetic microbeads as a synthetic platform for CD40L presentation, and this study tested liposomes as an alternative platform for CD40L presentation. When coupled with appropriate soluble signaling, the liposome effectively induced the hallmarks of B cell activation and subsequent germinal center (GC)-like reactions in vitro, namely a large proliferation (up to 27-fold expansion), antibody isotype class switch recombination, and differentiation into effector cells in a feeder-free, serum-free culture. More particularly, liposome-based CD40L presentation was more effective in the generation of antibody-secreting cells (ASCs) when compared to the microbead-based presentation. Up until now, liposomes have been mainly used for drug delivery, but the success of this study highlights their potential for use as a signal presentation platform in cell culture generally, and this research specifically is an important step on the path toward viable B cell-based immunotherapies

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.